


SGF29-IN-1

Cat. No.:	HY-158009
CAS No.:	6638-82-0
Molecular Formula:	C ₃₃ H ₃₃ N ₃ O ₃
Molecular Weight:	519.63
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)-associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia ^[1] .									
In Vitro	<p>SGF29-IN-1 (20 μM) inhibits Tudor domain of SGF29, blocks acetylation of H3K9 in SGF29-dependent leukemia cells MOLM13 and MV4-11^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MOLM13 and MV4-11</td> </tr> <tr> <td>Concentration:</td> <td>20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited acetylation of H3K9 and levels of RPL8 and RPS2.</td> </tr> </table>		Cell Line:	MOLM13 and MV4-11	Concentration:	20 μM	Incubation Time:	48 h	Result:	Inhibited acetylation of H3K9 and levels of RPL8 and RPS2.
Cell Line:	MOLM13 and MV4-11									
Concentration:	20 μM									
Incubation Time:	48 h									
Result:	Inhibited acetylation of H3K9 and levels of RPL8 and RPS2.									
In Vivo	<p>SGF29-IN-1 (5 mg/kg, i.p. every other day for 35 days) inhibits leukemia progression without significant toxicity in CD45 mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>MLL-AF9 xenograft CD45 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p., every other day for 35 days</td> </tr> <tr> <td>Result:</td> <td>Reduced percentage of 45.2 cells in peripheral blood and spleen. Improved survival rate of rats.</td> </tr> </table>		Animal Model:	MLL-AF9 xenograft CD45 mice ^[1]	Dosage:	5 mg/kg	Administration:	i.p., every other day for 35 days	Result:	Reduced percentage of 45.2 cells in peripheral blood and spleen. Improved survival rate of rats.
Animal Model:	MLL-AF9 xenograft CD45 mice ^[1]									
Dosage:	5 mg/kg									
Administration:	i.p., every other day for 35 days									
Result:	Reduced percentage of 45.2 cells in peripheral blood and spleen. Improved survival rate of rats.									

REFERENCES

[1]. Chan AKN, et al., Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. Sci Adv. 2024 Feb 23;10(8):eadk3127.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA